1. Pink Sheet
  3. >>US FDA

Warp Speed Lives Up To Its Name: FDA Planning Late October Vaccine Advisory Committee

 
• By Sarah Karlin-Smith

Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.

Covid19_Vaccine_Vial
COVID-19 vaccines may be the subject of an October FDA advisory committee • Source: Shutterstock

Preliminary plans for a late October meeting of the US Food and Drug Administration’s vaccine advisory committee suggests FDA may be laying the groundwork for a potentially quick decision on one or more COVID-19 vaccine candidates, the first of which are just commencing Phase III studies.

Paul Offit, a member of the Vaccines and Related Biological Products Advisory Committee and director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said he was told the committee will meet on 22 October and his assumption is the gathering will be used to discuss coronavirus

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership